Protective immunity against hepatitis C: Many shades of gray

Frontiers in Immunology

Volumn 5, Issue JUN, 2014, Pages

  Abdel Hakeem, Mohamed S ^a,b,c   Shoukry, Naglaa H ^a,b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c CAIRO UNIVERSITY   (Egypt)

Author keywords

Acute infection; Adaptive immunity; Antibodies; HCV reinfection; Hepatitis C; Innate immunity; NK cells; T cells

Indexed keywords

EID: 84905662172     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00274     Document Type: Review

References (260)

1. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology (2002) 36:S21-9. doi:10.1053/jhep.2002.36227
2. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology (2013) 57:1333-42. doi:10.1002/hep.26141
3. Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med (2013) 19:850-8. doi:10.1038/nm.3184
4. Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet (2000) 355:887-91. doi:10.1016/S0140-6736(99)06527-7
5. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis (2005) 5:558-67. doi:10.1016/S1473-3099(05)70216-4
6. Heathcote EJ. Prevention of hepatitis C virus-related hepatocellular carcinoma. Gastroenterology (2004) 127:S294-302. doi:10.1053/j.gastro.2004.09.044
7. Perz JF, Alter MJ. The coming wave of HCV-related liver disease: dilemmas and challenges. J Hepatol (2006) 44:441-3. doi:10.1016/j.jhep.2005.12.007
8. Charlton M. Natural history of hepatitis C and outcomes following liver transplantation. Clin Liver Dis (2003) 7:585-602. doi:10.1016/S1089-3261(03)00046-1
9. Brown RS. Hepatitis C and liver transplantation. Nature (2005) 436:973-8. doi:10.1038/nature04083
10. Hauri AM, Armstrong GL, Hutin YJ. The global burden of disease attributable to contaminated injections given in health care settings. Int J STD AIDS (2004) 15:7-16. doi:10.1258/095646204322637182
11. Liang TJ. Current progress in development of hepatitis C virus vaccines. Nat Med (2013) 19:869-78. doi:10.1038/nm.3183
12. Hagan H, Neurer J, Jordan AE, Des Jarlais DC, Wu J, Dombrowski K, et al. Hepatitis C virus infection among HIV-positive men who have sex with men: protocol for a systematic review and meta-analysis. Syst Rev (2014) 3:31. doi:10.1186/2046-4053-3-31
13. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science (1989) 244:359-62. doi:10.1126/science.2523562
14. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol (2007) 5:453-63. doi:10.1038/nrmicro1645
15. Scheel TK, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med (2013) 19:837-49. doi:10.1038/nm.3248
16. Egger D, Wolk B, Gosert R, Bianchi L, Blum HE, Moradpour D, et al. Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J Virol (2002) 76:5974-84. doi:10.1128/JVI.76.12.5974-5984.2002
17. Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science (2000) 290:1972-4. doi:10.1126/science.290.5498.1972
18. Krieger N, Lohmann V, Bartenschlager R. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J Virol (2001) 75:4614-24. doi:10.1128/JVI.75.10.4614-4624.2001
19. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest (1995) 96:224-30. doi:10.1172/jci118025
20. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment Web resource. Hepatology (2014) 59:318-27. doi:10.1002/hep.26744
21. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, et al. Binding of hepatitis C virus to CD81. Science (1998) 282:938-41. doi:10.1126/science.282.5390.938
22. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J (2002) 21:5017-25. doi:10.1093/emboj/cdf529
23. Evans MJ, Von Hahn T, Tscherne DM, Syder AJ, Panis M, Wolk B, et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature (2007) 446:801-5. doi:10.1038/nature05654
24. Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, De Jong YP, et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature (2009) 457:882-6. doi:10.1038/nature07684
25. Sainz B Jr, Barretto N, Martin DN, Hiraga N, Imamura M, Hussain S, et al. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med (2012) 18:281-5. doi:10.1038/nm.2581
26. Lupberger J, Zeisel MB, Xiao F, Thumann C, Fofana I, Zona L, et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med (2011) 17:589-95. doi:10.1038/nm.2341
27. Dubuisson J, Helle F, Cocquerel L. Early steps of the hepatitis C virus life cycle. Cell Microbiol (2008) 10:821-7. doi:10.1111/j.1462-5822.2007.01107.x
28. Bartenschlager R, Ahlborn-Laake L, Mous J, Jacobsen H. Kinetic and structural analyses of hepatitis C virus polyprotein processing. J Virol (1994) 68: 5045-55.
29. Merz A, Long G, Hiet MS, Brugger B, Chlanda P, Andre P, et al. Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome. J Biol Chem (2011) 286:3018-32. doi:10.1074/jbc.M110.175018
30. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, et al. Complete replication of hepatitis C virus in cell culture. Science (2005) 309:623-6. doi:10.1126/science.1114016
31. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med (2005) 11:791-6. doi:10.1038/nm0805-905b
32. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A (2005) 102:9294-9. doi:10.1073/pnas.0503596102
33. Tellinghuisen TL, Evans MJ, Von Hahn T, You S, Rice CM. Studying hepatitis C virus: making the best of a bad virus. J Virol (2007) 81:8853-67. doi:10.1128/jvi.00753-07
34. IOM. Chimpanzees in Biomedical and Behavioral Research: Assessing the Necessity. Washington DC: National Academies Press (2011).
35. Washburn ML, Bility MT, Zhang L, Kovalev GI, Buntzman A, Frelinger JA, et al. A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease. Gastroenterology (2011) 140:1334-44. doi:10.1053/j.gastro.2011.01.001
36. Billerbeck E, De Jong Y, Dorner M, De La Fuente C, Ploss A. Animal models for hepatitis C. Curr Top Microbiol Immunol (2013) 369:49-86. doi:10.1007/978-3-642-27340-7_3
37. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med (2001) 194:1395-406. doi:10.1084/jem.194.10.1395
38. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature (2005) 436:946-52. doi:10.1038/nature04079
39. Park SH, Rehermann B. Immune responses to HCV and other hepatitis viruses. Immunity (2014) 40:13-24. doi:10.1016/j.immuni.2013.12.010
40. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature (2005) 436:967. doi:10.1038/nature04082
41. Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, Astemborski J, et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science (2004) 305:872-4. doi:10.1126/science.1097670
42. Parham P. Immunology. NK cells lose their inhibition. Science (2004) 305:786-7. doi:10.1126/science.1102025
43. Knapp S, Warshow U, Hegazy D, Brackenbury L, Guha IN, Fowell A, et al. Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus. Hepatology (2010) 51:1168-75. doi:10.1002/hep.23477
44. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 461:399-401. doi:10.1038/nature08309
45. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet (2009) 41:1100-4. doi:10.1038/ng.447
46. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet (2009) 41:1105-9. doi:10.1038/ng.449
47. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 461:798-801. doi:10.1038/nature08463
48. Afdhal NH, Mchutchison JG, Zeuzem S, Mangia A, Pawlotsky JM, Murray JS, et al. Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology (2011) 53:336-45. doi:10.1002/hep.24052
49. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 45:164-71. doi:10.1038/ng.2521
50. Bibert S, Roger T, Calandra T, Bochud M, Cerny A, Semmo N, et al. IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J Exp Med (2013) 210:1109-16. doi:10.1084/jem.20130012
51. Dill MT, Duong FH, Vogt JE, Bibert S, Bochud PY, Terracciano L, et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology (2011) 140:1021-31. doi:10.1053/j.gastro.2010.11.039
52. Langhans B, Kupfer B, Braunschweiger I, Arndt S, Schulte W, Nischalke HD, et al. Interferon-lambda serum levels in hepatitis C. J Hepatol (2011) 54:859-65. doi:10.1016/j.jhep.2010.08.020
53. Park H, Serti E, Eke O, Muchmore B, Prokunina-Olsson L, Capone S, et al. IL-29 is the dominant type III interferon produced by hepatocytes during acute hepatitis C virus infection. Hepatology (2012) 56:2060-70. doi:10.1002/hep.25897
54. Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology (2010) 139:499-509. doi:10.1053/j.gastro.2010.04.049
55. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD, et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology (2010) 52:1888-96. doi:10.1002/hep.23912
56. McGilvray I, Feld JJ, Chen L, Pattullo V, Guindi M, Fischer S, et al. Hepatic cell-type specific gene expression better predicts HCV treatment outcome than IL28B genotype. Gastroenterology (2012) 142:1122-31.e1. doi:10.1053/j.gastro.2012.01.028
57. Dring MM, Morrison MH, Mcsharry BP, Guinan KJ, Hagan R, O'farrelly C, et al. Innate immune genes synergize to predict increased risk of chronic disease in hepatitis C virus infection. Proc Natl Acad Sci U S A (2011) 108:5736-41. doi:10.1073/pnas.1016358108
58. Suppiah V, Gaudieri S, Armstrong NJ, O'connor KS, Berg T, Weltman M, et al. IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study. PLoS Med (2011) 8:e1001092. doi:10.1371/journal.pmed.1001092
59. Duggal P, Thio CL, Wojcik GL, Goedert JJ, Mangia A, Latanich R, et al. Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med (2013) 158:235-45. doi:10.7326/0003-4819-158-4-201302190-00003
60. Rauch A, Gaudieri S, Thio C, Bochud PY. Host genetic determinants of spontaneous hepatitis C clearance. Pharmacogenomics (2009) 10:1819-37. doi:10.2217/pgs.09.121
61. Carrington M, Walker BD. Immunogenetics of spontaneous control of HIV. Annu Rev Med (2012) 63:131-45. doi:10.1146/annurev-med-062909-130018
62. Alric L, Fort M, Izopet J, Vinel JP, Charlet JP, Selves J, et al. Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection. Gastroenterology (1997) 113:1675-81. doi:10.1053/gast.1997.v113.pm9352872
63. Thursz M, Yallop R, Goldin R, Trepo C, Thomas HC. Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. Lancet (1999) 354:2119-24. doi:10.1016/S0140-6736(99)91443-5
64. Fanning LJ, Levis J, Kenny-Walsh E, Whelton M, O'sullivan K, Shanahan F. HLA class II genes determine the natural variance of hepatitis C viral load. Hepatology (2001) 33:224-30. doi:10.1053/jhep.2001.20642
65. Dazert E, Neumann-Haefelin C, Bressanelli S, Fitzmaurice K, Kort J, Timm J, et al. Loss of viral fitness and cross-recognition by CD8+ T cells limit HCV escape from a protective HLA-B27-restricted human immune response. J Clin Invest (2009) 119:376-86. doi:10.1172/JCI36587
66. Ashraf S, Nitschke K, Warshow UM, Brooks CR, Kim AY, Lauer GM, et al. Synergism of tapasin and human leukocyte antigens in resolving hepatitis C virus infection. Hepatology (2013) 58:881-9. doi:10.1002/hep.26415
67. Wolfl M, Rutebemberwa A, Mosbruger T, Mao Q, Li HM, Netski D, et al. Hepatitis C virus immune escape via exploitation of a hole in the T cell repertoire. J Immunol (2008) 181:6435-46. doi:10.4049/jimmunol.181.9.6435
68. Cook DN, Pisetsky DS, Schwartz DA. Toll-like receptors in the pathogenesis of human disease. Nat Immunol (2004) 5:975-9. doi:10.1038/ni1116
69. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol (2004) 5:987-95. doi:10.1038/ni1112
70. Horner SM, Gale M Jr. Regulation of hepatic innate immunity by hepatitis C virus. Nat Med (2013) 19:879-88. doi:10.1038/nm.3253
71. Wieland S, Makowska Z, Campana B, Calabrese D, Dill MT, Chung J, et al. Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver. Hepatology (2014) 59:2121-30. doi:10.1002/hep.26770
72. Gale M Jr, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature (2005) 436:939-45. doi:10.1038/nature04078
73. Randall G, Chen L, Panis M, Fischer AK, Lindenbach BD, Sun J, et al. Silencing of USP18 potentiates the antiviral activity of interferon against hepatitis C virus infection. Gastroenterology (2006) 131:1584-91. doi:10.1053/j.gastro.2006.08.043
74. Chen L, Sun J, Meng L, Heathcote J, Edwards AM, Mcgilvray ID. ISG15, a ubiquitin-like interferon-stimulated gene, promotes hepatitis C virus production in vitro: implications for chronic infection and response to treatment. J Gen Virol (2010) 91:382-8. doi:10.1099/vir.0.015388-0
75. Bigger CB, Brasky KM, Lanford RE. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J Virol (2001) 75:7059-66. doi:10.1128/JVI.75.15.7059-7066.2001
76. Su AI, Pezacki JP, Wodicka L, Brideau AD, Supekova L, Thimme R, et al. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A (2002) 99:15669-74. doi:10.1073/pnas.202608199
77. Thimme R, Bukh J, Spangenberg HC, Wieland S, Pemberton J, Steiger C, et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci U S A (2002) 99:15661-8. doi:10.1073/pnas.202608299
78. Bigger CB, Guerra B, Brasky KM, Hubbard G, Beard MR, Luxon BA, et al. Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J Virol (2004) 78:13779-92. doi:10.1128/jvi.78.24.13779-13792.2004
79. Marukian S, Andrus L, Sheahan TP, Jones CT, Charles ED, Ploss A, et al. Hepatitis C virus induces interferon-lambda and interferon-stimulated genes in primary liver cultures. Hepatology (2011) 54:1913-23. doi:10.1002/hep.24580
80. Thomas E, Gonzalez VD, Li Q, Modi AA, Chen W, Noureddin M, et al. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology (2012) 142:978-88. doi:10.1053/j.gastro.2011.12.055
81. Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, Macdonald MR, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology (2006) 131:1887-98. doi:10.1053/j.gastro.2006.09.052
82. Olagnier D, Hiscott J. Type I and type III interferon-induced immune response: it's a matter of kinetics and magnitude. Hepatology (2014) 59:1225-8. doi:10.1002/hep.26959
83. Sheahan T, Imanaka N, Marukian S, Dorner M, Liu P, Ploss A, et al. Interferon lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness. Cell Host Microbe (2014) 15:190-202. doi:10.1016/j.chom.2014.01.007
84. Lau DT, Negash A, Chen J, Crochet N, Sinha M, Zhang Y, et al. Innate immune tolerance and the role of kupffer cells in differential responses to interferon therapy among patients with HCV genotype 1 infection. Gastroenterology (2013) 144:402.e-13.e. doi:10.1053/j.gastro.2012.10.044
85. Zhang S, Kodys K, Li K, Szabo G. Human type 2 myeloid dendritic cells produce interferon-lambda and amplify interferon-alpha in response to hepatitis C virus infection. Gastroenterology (2013) 144:414.e-25.e. doi:10.1053/j.gastro.2012.10.034
86. Takahashi K, Asabe S, Wieland S, Garaigorta U, Gastaminza P, Isogawa M, et al. Plasmacytoid dendritic cells sense hepatitis C virus-infected cells, produce interferon, and inhibit infection. Proc Natl Acad Sci U S A (2010) 107:7431-6. doi:10.1073/pnas.1002301107
87. Dreux M, Garaigorta U, Boyd B, Decembre E, Chung J, Whitten-Bauer C, et al. Short-range exosomal transfer of viral RNA from infected cells to plasmacytoid dendritic cells triggers innate immunity. Cell Host Microbe (2012) 12:558-70. doi:10.1016/j.chom.2012.08.010
88. Taylor DR, Shi ST, Romano PR, Barber GN, Lai MM. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science (1999) 285:107-10. doi:10.1126/science.285.5424.107
89. Taguchi T, Nagano-Fujii M, Akutsu M, Kadoya H, Ohgimoto S, Ishido S, et al. Hepatitis C virus NS5A protein interacts with 2',5'-oligoadenylate synthetase and inhibits antiviral activity of IFN in an IFN sensitivity-determining region-independent manner. J Gen Virol (2004) 85:959-69. doi:10.1099/vir.0.19513-0
90. Foy E, Li K, Sumpter R Jr, Loo YM, Johnson CL, Wang C, et al. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc Natl Acad Sci U S A (2005) 102:2986-91. doi:10.1073/pnas.0408707102
91. Chen L, Borozan I, Feld J, Sun J, Tannis LL, Coltescu C, et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology (2005) 128:1437. doi:10.1053/j.gastro.2005.01.059
92. Jost S, Altfeld M. Control of human viral infections by natural killer cells. Annu Rev Immunol (2013) 31:163-94. doi:10.1146/annurev-immunol-032712-100001
93. Doherty DG, O'Farrelly C. Innate and adaptive lymphoid cells in the human liver. Immunol Rev (2000) 174:5-20. doi:10.1034/j.1600-0528.2002.017416.x
94. Crispe IN. The liver as a lymphoid organ. Annu Rev Immunol (2009) 27:147-63. doi:10.1146/annurev.immunol.021908.132629
95. Werner JM, Heller T, Gordon AM, Sheets A, Sherker AH, Kessler E, et al. Innate immune responses in hepatitis C virus exposed healthcare workers who do not develop acute infection. Hepatology (2013) 58:1621-31. doi:10.1002/hep.26353
96. Golden-Mason L, Cox AL, Randall JA, Cheng L, Rosen HR. Increased natural killer cell cytotoxicity and NKp30 expression protects against hepatitis C virus infection in high-risk individuals and inhibits replication in vitro. Hepatology (2010) 52:1581-9. doi:10.1002/hep.23896
97. Alter G, Jost S, Rihn S, Reyor LL, Nolan BE, Ghebremichael M, et al. Reduced frequencies of NKp30+NKp46+, CD161+, and NKG2D+ NK cells in acute HCV infection may predict viral clearance. J Hepatol (2011) 55:278-88. doi:10.1016/j.jhep.2010.11.030
98. Amadei B, Urbani S, Cazaly A, Fisicaro P, Zerbini A, Ahmed P, et al. Activation of natural killer cells during acute infection with hepatitis C virus. Gastroenterology (2010) 138:1536-45. doi:10.1053/j.gastro.2010.01.006
99. Pelletier S, Drouin C, Bedard N, Khakoo SI, Bruneau J, Shoukry NH. Increased degranulation of natural killer cells during acute HCV correlates with the magnitude of virus-specific T cell responses. J Hepatol (2010) 53:805-16. doi:10.1016/j.jhep.2010.05.013
100. Ahlenstiel G, Titerence RH, Koh C, Edlich B, Feld JJ, Rotman Y, et al. Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Gastroenterology (2010) 138(325-335):e321-2. doi:10.1053/j.gastro.2009.08.066
101. Bonorino P, Ramzan M, Camous X, Dufeu-Duchesne T, Thelu MA, Sturm N, et al. Fine characterization of intrahepatic NK cells expressing natural killer receptors in chronic hepatitis B and C. J Hepatol (2009) 51:458-67. doi:10.1016/j.jhep.2009.05.030
102. Oliviero B, Varchetta S, Paudice E, Michelone G, Zaramella M, Mavilio D, et al. Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology (2009) 137:1151-60. doi:10.1053/j.gastro.2009.05.047
103. Shoukry NH, Pelletier S, Chang KM. A view to natural killer cells in hepatitis C. Gastroenterology (2011) 141:1144-8. doi:10.1053/j.gastro.2011.08.025
104. Golden-Mason L, Rosen HR. Natural killer cells: multifaceted players with key roles in hepatitis C immunity. Immunol Rev (2013) 255:68-81. doi:10.1111/imr.12090
105. Rehermann B. Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med (2013) 19:859-68. doi:10.1038/nm.3251
106. Corado J, Toro F, Rivera H, Bianco NE, Deibis L, De Sanctis JB. Impairment of natural killer (NK) cytotoxic activity in hepatitis C virus (HCV) infection. Clin Exp Immunol (1997) 109:451-7. doi:10.1046/j.1365-2249.1997.4581355.x
107. Meier UC, Owen RE, Taylor E, Worth A, Naoumov N, Willberg C, et al. Shared alterations in NK cell frequency, phenotype, and function in chronic human immunodeficiency virus and hepatitis C virus infections. J Virol (2005) 79:12365-74. doi:10.1128/JVI.79.19.12365-12374.2005
108. Nattermann J, Feldmann G, Ahlenstiel G, Langhans B, Sauerbruch T, Spengler U. Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis C. Gut (2006) 55:869-77. doi:10.1136/gut.2005.076463
109. Lunemann S, Malone DF, Hengst J, Port K, Grabowski J, Deterding K, et al. Compromised function of natural killer cells in acute and chronic viral hepatitis. J Infect Dis (2014) 209:1362-73. doi:10.1093/infdis/jit561
110. Crotta S, Stilla A, Wack A, D'bndrea A, Nuti S, D'oro U, et al. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med (2002) 195:35-41. doi:10.1084/jem.20011124
111. Tseng CT, Klimpel GR. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J Exp Med (2002) 195:43-9. doi:10.1084/jem.20011145
112. Yoon JC, Shiina M, Ahlenstiel G, Rehermann B. Natural killer cell function is intact after direct exposure to infectious hepatitis C virions. Hepatology (2009) 49:12-21. doi:10.1002/hep.22624
113. Yoon JC, Lim JB, Park JH, Lee JM. Cell-to-cell contact with hepatitis C virus-infected cells reduces functional capacity of natural killer cells. J Virol (2011) 85:12557-69. doi:10.1128/jvi.00838-11
114. Waggoner SN, Cornberg M, Selin LK, Welsh RM. Natural killer cells act as rheostats modulating antiviral T cells. Nature (2012) 481:394-8. doi:10.1038/nature10624
115. Peppa D, Gill US, Reynolds G, Easom NJ, Pallett LJ, Schurich A, et al. Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion. J Exp Med (2013) 210:99-114. doi:10.1084/jem.20121172
116. Marcenaro E, Carlomagno S, Pesce S, Moretta A, Sivori S. NK/DC crosstalk in anti-viral response. Adv Exp Med Biol (2012) 946:295-308. doi:10.1007/978-1-4614-0106-3_17
117. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature (2007) 449:419-26. doi:10.1038/nature06175
118. Longman RS, Talal AH, Jacobson IM, Albert ML, Rice CM. Presence of functional dendritic cells in patients chronically infected with hepatitis C virus. Blood (2004) 103:1026-9. doi:10.1182/blood-2003-04-1339
119. Wertheimer AM, Bakke A, Rosen HR. Direct enumeration and functional assessment of circulating dendritic cells in patients with liver disease. Hepatology (2004) 40:335-45. doi:10.1002/hep.20306
120. Longman RS, Talal AH, Jacobson IM, Rice CM, Albert ML. Normal functional capacity in circulating myeloid and plasmacytoid dendritic cells in patients with chronic hepatitis C. J Infect Dis (2005) 192:497-503. doi:10.1086/431523
121. Piccioli D, Tavarini S, Nuti S, Colombatto P, Brunetto M, Bonino F, et al. Comparable functions of plasmacytoid and monocyte-derived dendritic cells in chronic hepatitis C patients and healthy donors. J Hepatol (2005) 42:61-7. doi:10.1016/j.jhep.2004.09.014
122. Pelletier S, Bedard N, Said E, Ancuta P, Bruneau J, Shoukry NH. Sustained hyperresponsiveness of dendritic cells is associated with spontaneous resolution of acute hepatitis C. J Virol (2013) 87:6769-81. doi:10.1128/jvi.02445-12
123. Bain C, Fatmi A, Zoulim F, Zarski JP, Trepo C, Inchauspe G. Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology (2001) 120:512-24. doi:10.1053/gast.2001.21212
124. Dolganiuc A, Kodys K, Kopasz A, Marshall C, Do T, Romics L Jr, et al. Hepatitis C virus core and nonstructural protein 3 proteins induce pro- and anti-inflammatory cytokines and inhibit dendritic cell differentiation. J Immunol (2003) 170:5615-24. doi:10.4049/jimmunol.170.11.5615
125. Sarobe P, Lasarte JJ, Zabaleta A, Arribillaga L, Arina A, Melero I, et al. Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses. J Virol (2003) 77:10862-71. doi:10.1128/JVI.77.20.10862-10871.2003
126. Rodrigue-Gervais IG, Jouan L, Beaule G, Sauve D, Bruneau J, Willems B, et al. Poly(I:C) and lipopolysaccharide innate sensing functions of circulating human myeloid dendritic cells are affected in vivo in hepatitis C virus-infected patients. J Virol (2007) 81:5537-46. doi:10.1128/JVI.01741-06
127. Dolganiuc A, Paek E, Kodys K, Thomas J, Szabo G. Myeloid dendritic cells of patients with chronic HCV infection induce proliferation of regulatory T lymphocytes. Gastroenterology (2008) 135:2119-27. doi:10.1053/j.gastro.2008.07.082
128. Larsson M, Babcock E, Grakoui A, Shoukry N, Lauer G, Rice C, et al. Lack of phenotypic and functional impairment in dendritic cells from chimpanzees chronically infected with hepatitis C virus. J Virol (2004) 78:6151-61. doi:10.1128/JVI.78.12.6151-6161.2004
129. Decalf J, Fernandes S, Longman R, Ahloulay M, Audat F, Lefrerre F, et al. Plasmacytoid dendritic cells initiate a complex chemokine and cytokine network and are a viable drug target in chronic HCV patients. J Exp Med (2007) 204:2423-37. doi:10.1084/jem.20070814
130. Cooper S, Erickson AL, Adams EJ, Kansopon J, Weiner AJ, Chien DY, et al. Analysis of a successful immune response against hepatitis C virus. Immunity (1999) 10:439-49. doi:10.1016/S1074-7613(00)80044-8
131. Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med (2000) 191:1499-512. doi:10.1084/jem.191.9.1499
132. Smyk-Pearson S, Tester IA, Lezotte D, Sasaki AW, Lewinsohn DM, Rosen HR. Differential antigenic hierarchy associated with spontaneous recovery from hepatitis C virus infection: implications for vaccine design. J Infect Dis (2006) 194:454-63. doi:10.1086/505714
133. Lauer GM, Ouchi K, Chung RT, Nguyen TN, Day CL, Purkis DR, et al. Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. J Virol (2002) 76:6104-13. doi:10.1128/JVI.76.12.6104-6113.2002
134. Lauer GM, Barnes E, Lucas M, Timm J, Ouchi K, Kim AY, et al. High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology (2004) 127:924-36. doi:10.1053/j.gastro.2004.06.015
135. Erickson AL, Kimura Y, Igarashi S, Eichelberger J, Houghton M, Sidney J, et al. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity (2001) 15:883-95. doi:10.1016/S1074-7613(01)00245-X
136. Bowen DG, Walker CM. Mutational escape from CD8+ T cell immunity: HCV evolution, from chimpanzees to man. J Exp Med (2005) 201:1709-14. doi:10.1084/jem.20050808
137. Cox AL, Mosbruger T, Mao Q, Liu Z, Wang XH, Yang HC, et al. Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med (2005) 201:1741-52. doi:10.1084/jem.20050121
138. Timm J, Lauer GM, Kavanagh DG, Sheridan I, Kim AY, Lucas M, et al. CD8 epitope escape and reversion in acute HCV infection. J Exp Med (2004) 200:1593-604. doi:10.1084/jem.20041006
139. Gaudieri S, Rauch A, Park LP, Freitas E, Herrmann S, Jeffrey G, et al. Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection. J Virol (2006) 80:11094-104. doi:10.1128/jvi.00912-06
140. Soderholm J, Ahlen G, Kaul A, Frelin L, Alheim M, Barnfield C, et al. Relation between viral fitness and immune escape within the hepatitis C virus protease. Gut (2006) 55:266-74. doi:10.1136/gut.2005.072231
141. Uebelhoer L, Han JH, Callendret B, Mateu G, Shoukry NH, Hanson HL, et al. Stable cytotoxic T cell escape mutation in hepatitis C virus is linked to maintenance of viral fitness. PLoS Pathog (2008) 4:e1000143. doi:10.1371/journal.ppat.1000143
142. Neumann-Haefelin C, Mckiernan S, Ward S, Viazov S, Spangenberg HC, Killinger T, et al. Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution. Hepatology (2006) 43:563-72. doi:10.1002/hep.21049
143. Neumann-Haefelin C, Oniangue-Ndza C, Kuntzen T, Schmidt J, Nitschke K, Sidney J, et al. Human leukocyte antigen B27 selects for rare escape mutations that significantly impair hepatitis C virus replication and require compensatory mutations. Hepatology (2011) 54:1157-66. doi:10.1002/hep.24541
144. Meyer-Olson D, Shoukry NH, Brady KW, Kim H, Olson DP, Hartman K, et al. Limited T cell receptor diversity of HCV-specific T cell responses is associated with CTL escape. J Exp Med (2004) 200:307-19. doi:10.1084/jem.20040638
145. Appay V, Iglesias MC. Antigen sensitivity and T-cell receptor avidity as critical determinants of HIV control. Curr Opin HIV AIDS (2011) 6:157-62. doi:10.1097/COH.0b013e3283453dfd
146. Badr G, Bedard N, Abdel-Hakeem MS, Trautmann L, Willems B, Villeneuve JP, et al. Early interferon therapy for hepatitis C virus infection rescues polyfunctional, long-lived CD8+ memory T cells. J Virol (2008) 82:10017-31. doi:10.1128/JVI.01083-08
147. Shoukry NH, Grakoui A, Houghton M, Chien DY, Ghrayeb J, Reimann KA, et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med (2003) 197:1645-55. doi:10.1084/jem.20030239
148. Golden-Mason L, Burton JR Jr, Castelblanco N, Klarquist J, Benlloch S, Wang C, et al. Loss of IL-7 receptor alpha-chain (CD127) expression in acute HCV infection associated with viral persistence. Hepatology (2006) 44:1098-109. doi:10.1002/hep.21365
149. Shin EC, Park SH, Nascimbeni M, Major M, Caggiari L, De Re V, et al. The frequency of CD127+ HCV-specific T cells but not the expression of exhaustion markers predict the outcome of acute hepatitis C virus infection. J Virol (2013) 87:4772-7. doi:10.1128/jvi.03122-12
150. Kaech SM, Tan JT, Wherry EJ, Konieczny BT, Surh CD, Ahmed R. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol (2003) 4:1191-8. doi:10.1038/ni1009
151. Urbani S, Amadei B, Tola D, Massari M, Schivazappa S, Missale G, et al. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J Virol (2006) 80:11398-403. doi:10.1128/JVI.01177-06
152. Bowen DG, Shoukry NH, Grakoui A, Fuller MJ, Cawthon AG, Dong C, et al. Variable patterns of programmed death-1 expression on fully functional memory T cells after spontaneous resolution of hepatitis C virus infection. J Virol (2008) 82:5109-14. doi:10.1128/JVI.00060-08
153. Kasprowicz V, Schulze Zur Wiesch J, Kuntzen T, Nolan BE, Longworth S, Berical A, et al. High level of PD-1 expression on hepatitis C virus (HCV)-specific CD8+ and CD4+ T cells during acute HCV infection, irrespective of clinical outcome. J Virol (2008) 82:3154-60. doi:10.1128/JVI.02474-07
154. Bengsch B, Seigel B, Ruhl M, Timm J, Kuntz M, Blum HE, et al. Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation. PLoS Pathog (2010) 6:e1000947. doi:10.1371/journal.ppat.1000947
155. Kared H, Fabre T, Bedard N, Bruneau J, Shoukry NH. Galectin-9 and IL-21 mediate cross-regulation between Th17 and Treg cells during acute hepatitis C. PLoS Pathog (2013) 9:e1003422. doi:10.1371/journal.ppat.1003422
156. Mengshol JA, Golden-Mason L, Arikawa T, Smith M, Niki T, Mcwilliams R, et al. A crucial role for Kupffer cell-derived galectin-9 in regulation of T cell immunity in hepatitis C infection. PLoS One (2010) 5:e9504. doi:10.1371/journal.pone.0009504
157. Penna A, Pilli M, Zerbini A, Orlandini A, Mezzadri S, Sacchelli L, et al. Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection. Hepatology (2007) 45:588-601. doi:10.1002/hep.21541
158. Nakamoto N, Cho H, Shaked A, Olthoff K, Valiga ME, Kaminski M, et al. Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog (2009) 5:e1000313. doi:10.1371/journal.ppat.1000313
159. McMahan RH, Golden-Mason L, Nishimura MI, Mcmahon BJ, Kemper M, Allen TM, et al. Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J Clin Invest (2010) 120:4546-57. doi:10.1172/jci43127
160. He XS, Rehermann B, Lopez-Labrador FX, Boisvert J, Cheung R, Mumm J, et al. Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers. Proc Natl Acad Sci U S A (1999) 96:5692-7. doi:10.1073/pnas.96.10.5692
161. Radziewicz H, Ibegbu CC, Fernandez ML, Workowski KA, Obideen K, Wehbi M, et al. Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J Virol (2007) 81:2545-53. doi:10.1128/JVI.02021-06
162. Kroy DC, Ciuffreda D, Cooperrider JH, Tomlinson M, Hauck GD, Aneja J, et al. Liver environment and HCV replication affect human T-cell phenotype and expression of inhibitory receptors. Gastroenterology (2014) 146:550-61. doi:10.1053/j.gastro.2013.10.022
163. Lechner F, Gruener NH, Urbani S, Uggeri J, Santantonio T, Kammer AR, et al. CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained. Eur J Immunol (2000) 30:2479-87. doi:10.1002/1521-4141(200009)30:9<2479::AID-IMMU2479>3.0.CO;2-B
164. Almeida JR, Price DA, Papagno L, Arkoub ZA, Sauce D, Bornstein E, et al. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med (2007) 204:2473-85. doi:10.1084/jem.20070784
165. Yi JS, Du M, Zajac AJ. A vital role for interleukin-21 in the control of a chronic viral infection. Science (2009) 324:1572-6. doi:10.1126/science.1175194
166. Lauer GM. Immune responses to hepatitis C virus (HCV) infection and the prospects for an effective HCV vaccine or immunotherapies. J Infect Dis (2013) 207(Suppl 1):S7-12. doi:10.1093/infdis/jis762
167. Gruener NH, Lechner F, Jung MC, Diepolder H, Gerlach T, Lauer G, et al. Sustained dysfunction of antiviral CD8(+) T lymphocytes after infection with hepatitis C virus. J Virol (2001) 75:5550-8. doi:10.1128/JVI.75.12.5550-5558.2001
168. Appay V, Dunbar PR, Callan M, Klenerman P, Gillespie GM, Papagno L, et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med (2002) 8:379-85. doi:10.1038/nm0402-379
169. Wedemeyer H, He XS, Nascimbeni M, Davis AR, Greenberg HB, Hoofnagle JH, et al. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol (2002) 169:3447-58. doi:10.4049/jimmunol.169.6.3447
170. Callendret B, Walker C. A siege of hepatitis: immune boost for viral hepatitis. Nat Med (2011) 17:252-3. doi:10.1038/nm0311-252
171. Fuller MJ, Callendret B, Zhu B, Freeman GJ, Hasselschwert DL, Satterfield W, et al. Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1). Proc Natl Acad Sci U S A (2013) 110:15001-6. doi:10.1073/pnas.1312772110
172. Gardiner D, Lalezari J, Lawitz E, Dimicco M, Ghalib R, Reddy KR, et al. A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. PLoS One (2013) 8:e63818. doi:10.1371/journal.pone.0063818
173. Bucks CM, Norton JA, Boesteanu AC, Mueller YM, Katsikis PD. Chronic antigen stimulation alone is sufficient to drive CD8+ T cell exhaustion. J Immunol (2009) 182:6697-708. doi:10.4049/jimmunol.0800997
174. Mueller SN, Ahmed R. High antigen levels are the cause of T cell exhaustion during chronic viral infection. Proc Natl Acad Sci U S A (2009) 106:8623-8. doi:10.1073/pnas.0809818106
175. Rutebemberwa A, Ray SC, Astemborski J, Levine J, Liu L, Dowd KA, et al. High-programmed death-1 levels on hepatitis C virus-specific T cells during acute infection are associated with viral persistence and require preservation of cognate antigen during chronic infection. J Immunol (2008) 181:8215-25. doi:10.4049/jimmunol.181.12.8215
176. Abdel-Hakeem MS, Bedard N, Badr G, Ostrowski M, Sekaly RP, Bruneau J, et al. Comparison of immune restoration in early versus late alpha interferon therapy against hepatitis C virus. J Virol (2010) 84:10429-35. doi:10.1128/JVI.01094-10
177. Kasprowicz V, Kang YH, Lucas M, Schulze Zur Wiesch J, Kuntzen T, Fleming V, et al. Hepatitis C virus (HCV) sequence variation induces an HCV-specific T-cell phenotype analogous to spontaneous resolution. J Virol (2010) 84:1656-63. doi:10.1128/JVI.01499-09
178. Diepolder HM, Zachoval R, Hoffmann RM, Wierenga EA, Santantonio T, Jung MC, et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet (1995) 346:1006-7. doi:10.1016/S0140-6736(95)91691-1
179. Missale G, Bertoni R, Lamonaca V, Valli A, Massari M, Mori C, et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest (1996) 98:706-14. doi:10.1172/JCI118842
180. Gerlach JT, Diepolder HM, Jung MC, Gruener NH, Schraut WW, Zachoval R, et al. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology (1999) 117:933-41. doi:10.1016/S0016-5085(99)70353-7
181. Day CL, Lauer GM, Robbins GK, Mcgovern B, Wurcel AG, Gandhi RT, et al. Broad specificity of virus-specific CD4(+) T-helper-cell responses in resolved hepatitis C virus infection. J Virol (2002) 76:12584-95. doi:10.1128/JVI.76.24.12584-12595.2002
182. Shoukry NH, Sidney J, Sette A, Walker CM. Conserved hierarchy of helper T cell responses in a chimpanzee during primary and secondary hepatitis C virus infections. J Immunol (2004) 172:483-92. doi:10.4049/jimmunol.172.1.483
183. Schulze Zur Wiesch J, Lauer GM, Day CL, Kim AY, Ouchi K, Duncan JE, et al. Broad repertoire of the CD4+ Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes. J Immunol (2005) 175:3603-13. doi:10.4049/jimmunol.175.6.3603
184. Fleming VM, Harcourt G, Barnes E, Klenerman P. Virological footprint of CD4+ T-cell responses during chronic hepatitis C virus infection. J Gen Virol (2010) 91:1396-406. doi:10.1099/vir.0.017699-0
185. Fuller MJ, Shoukry NH, Gushima T, Bowen DG, Callendret B, Campbell KJ, et al. Selection-driven immune escape is not a significant factor in the failure of CD4 T cell responses in persistent hepatitis C virus infection. Hepatology (2010) 51:378-87. doi:10.1002/hep.23319
186. Day CL, Seth NP, Lucas M, Appel H, Gauthier L, Lauer GM, et al. Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. J Clin Invest (2003) 112:831-42. doi:10.1172/JCI18509
187. Lucas M, Ulsenheimer A, Pfafferot K, Heeg MH, Gaudieri S, Gruner N, et al. Tracking virus-specific CD4+ T cells during and after acute hepatitis C virus infection. PLoS One (2007) 2:e649. doi:10.1371/journal.pone.0000649
188. Semmo N, Day CL, Ward SM, Lucas M, Harcourt G, Loughry A, et al. Preferential loss of IL-2-secreting CD4+ T helper cells in chronic HCV infection. Hepatology (2005) 41:1019-28. doi:10.1002/hep.20669
189. Schulze Zur Wiesch J, Ciuffreda D, Lewis-Ximenez L, Kasprowicz V, Nolan BE, Streeck H, et al. Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence. J Exp Med (2012) 209:61-75. doi:10.1084/jem.20100388
190. Raziorrouh B, Ulsenheimer A, Schraut W, Heeg M, Kurktschiev P, Zachoval R, et al. Inhibitory molecules that regulate expansion and restoration of HCV-specific CD4+ T cells in patients with chronic infection. Gastroenterology (2011) 141:1422-31. doi:10.1053/j.gastro.2011.07.004
191. Grakoui A, Shoukry NH, Woollard DJ, Han JH, Hanson HL, Ghrayeb J, et al. HCV persistence and immune evasion in the absence of memory T cell help. Science (2003) 302:659-62. doi:10.1126/science.1088774
192. Johnson LD, Jameson SC. Immunology. A chronic need for IL-21. Science (2009) 324:1525-6. doi:10.1126/science.1176487
193. Manigold T, Racanelli V. T-cell regulation by CD4 regulatory T cells during hepatitis B and C virus infections: facts and controversies. Lancet Infect Dis (2007) 7:804-13. doi:10.1016/S1473-3099(07)70289-X
194. Ebinuma H, Nakamoto N, Li Y, Price DA, Gostick E, Levine BL, et al. Identification and in vitro expansion of functional antigen-specific CD25+ FoxP3+ regulatory T cells in hepatitis C virus infection. J Virol (2008) 82:5043-53. doi:10.1128/JVI.01548-07
195. Rowan AG, Fletcher JM, Ryan EJ, Moran B, Hegarty JE, O'farrelly C, et al. Hepatitis C virus-specific Th17 cells are suppressed by virus-induced TGF-beta. J Immunol (2008) 181:4485-94. doi:10.4049/jimmunol.181.7.4485
196. Foster RG, Golden-Mason L, Rutebemberwa A, Rosen HR. Interleukin (IL)-17/IL-22-producing T cells enriched within the liver of patients with chronic hepatitis C viral (HCV) infection. Dig Dis Sci (2012) 57:381-9. doi:10.1007/s10620-011-1997-z
197. Park SH, Veerapu NS, Shin EC, Biancotto A, Mccoy JP, Capone S, et al. Subinfectious hepatitis C virus exposures suppress T cell responses against subsequent acute infection. Nat Med (2013) 19:1638-42. doi:10.1038/nm.3408
198. Yang XO, Nurieva R, Martinez GJ, Kang HS, Chung Y, Pappu BP, et al. Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity (2008) 29:44-56. doi:10.1016/j.immuni.2008.05.007
199. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol (2005) 5:215-29. doi:10.1038/nri1573
200. Dustin LB, Rice CM. Flying under the radar: the immunobiology of hepatitis C. Annu Rev Immunol (2007) 25:71-99. doi:10.1146/annurev.immunol.25.022106.141602
201. Farci P, Shimoda A, Wong D, Cabezon T, De Gioannis D, Strazzera A, et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A (1996) 93:15394-9. doi:10.1073/pnas.93.26.15394
202. Shimizu YK, Igarashi H, Kiyohara T, Cabezon T, Farci P, Purcell RH, et al. A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures. Virology (1996) 223:409-12. doi:10.1006/viro.1996.0497
203. Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science (2000) 288:339-44. doi:10.1126/science.288.5464.339
204. Bassett SE, Thomas DL, Brasky KM, Lanford RE. Viral persistence, antibody to E1 and E2, and hypervariable region 1 sequence stability in hepatitis C virus-inoculated chimpanzees. J Virol (1999) 73:1118-26.
205. Major ME, Mihalik K, Fernandez J, Seidman J, Kleiner D, Kolykhalov AA, et al. Long-term follow-up of chimpanzees inoculated with the first infectious clone for hepatitis C virus. J Virol (1999) 73:3317-25
206. Logvinoff C, Major ME, Oldach D, Heyward S, Talal A, Balfe P, et al. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci U S A (2004) 101:10149-54. doi:10.1073/pnas.0403519101
207. Netski DM, Mosbruger T, Depla E, Maertens G, Ray SC, Hamilton RG, et al. Humoral immune response in acute hepatitis C virus infection. Clin Infect Dis (2005) 41:667-75. doi:10.1086/432478
208. Semmo N, Lucas M, Krashias G, Lauer G, Chapel H, Klenerman P. Maintenance of HCV-specific T-cell responses in antibody-deficient patients a decade after early therapy. Blood (2006) 107:4570-1. doi:10.1182/blood-2005-11-4522
209. Von Hahn T, Yoon JC, Alter H, Rice CM, Rehermann B, Balfe P, et al. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology (2007) 132:667-78. doi:10.1053/j.gastro.2006.12.008
210. Pestka JM, Zeisel MB, Blaser E, Schurmann P, Bartosch B, Cosset FL, et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A (2007) 104:6025-30. doi:10.1073/pnas.0607026104
211. Law M, Maruyama T, Lewis J, Giang E, Tarr AW, Stamataki Z, et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med (2008) 14:25-7. doi:10.1038/nm1698
212. Giang E, Dorner M, Prentoe JC, Dreux M, Evans MJ, Bukh J, et al. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc Natl Acad Sci U S A (2012) 109:6205-10. doi:10.1073/pnas.1114927109
213. Fauci AS, Folkers GK, Dieffenbach CW. HIV-AIDS: much accomplished, much to do. Nat Immunol (2013) 14:1104-7. doi:10.1038/ni.2735
214. Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med (2003) 197:633-42. doi:10.1084/jem.20021756
215. Hsu M, Zhang J, Flint M, Logvinoff C, Cheng-Mayer C, Rice CM, et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A (2003) 100:7271-6. doi:10.1073/pnas.0832180100
216. Dowd KA, Netski DM, Wang XH, Cox AL, Ray SC. Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus. Gastroenterology (2009) 136:2377-86. doi:10.1053/j.gastro.2009.02.080
217. Osburn WO, Snider AE, Wells BL, Latanich R, Bailey JR, Thomas DL, et al. Clearance of Hepatitis C infection is associated with early appearance of broad neutralizing antibody responses. Hepatology (2014) 59:2140-51. doi:10.1002/hep.27013
218. Baum LL. Role of humoral immunity in host defense against HIV. Curr HIV/AIDS Rep (2010) 7:11-8. doi:10.1007/s11904-009-0036-6
219. Berger CT, Alter G. Natural killer cells in spontaneous control of HIV infection. Curr Opin HIV AIDS (2011) 6:208-13. doi:10.1097/COH.0b013e3283457798
220. Wren L, Kent SJ. HIV Vaccine efficacy trial: glimmers of hope and the potential role of antibody-dependent cellular cytotoxicity. Hum Vaccin (2011) 7:466-73. doi:10.4161/hv.7.4.14123
221. Nattermann J, Schneiders AM, Leifeld L, Langhans B, Schulz M, Inchauspe G, et al. Serum antibodies against the hepatitis C virus E2 protein mediate antibody-dependent cellular cytotoxicity (ADCC). J Hepatol (2005) 42:499-504. doi:10.1016/j.jhep.2004.12.018
222. Weiner AJ, Geysen HM, Christopherson C, Hall JE, Mason TJ, Saracco G, et al. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad Sci U S A (1992) 89:3468-72. doi:10.1073/pnas.89.8.3468
223. Liu L, Fisher BE, Dowd KA, Astemborski J, Cox AL, Ray SC. Acceleration of hepatitis C virus envelope evolution in humans is consistent with progressive humoral immune selection during the transition from acute to chronic infection. J Virol (2010) 84:5067-77. doi:10.1128/JVI.02265-09
224. Helle F, Goffard A, Morel V, Duverlie G, Mckeating J, Keck ZY, et al. The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J Virol (2007) 81:8101-11. doi:10.1128/JVI.00127-07
225. Khan AG, Whidby J, Miller MT, Scarborough H, Zatorski AV, Cygan A, et al. Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2. Nature (2014) 509:381-4. doi:10.1038/nature13117
226. Kong L, Giang E, Nieusma T, Kadam RU, Cogburn KE, Hua Y, et al. Hepatitis C virus E2 envelope glycoprotein core structure. Science (2013) 342:1090-4. doi:10.1126/science.1243876
227. Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med (2000) 6:578-82. doi:10.1038/75063
228. Koziel MJ, Wong DK, Dudley D, Houghton M, Walker BD. Hepatitis C virus-specific cytolytic T lymphocyte and T helper cell responses in seronegative persons. J Infect Dis (1997) 176:859-66. doi:10.1086/516546
229. Scognamiglio P, Accapezzato D, Casciaro MA, Cacciani A, Artini M, Bruno G, et al. Presence of effector CD8+ T cells in hepatitis C virus-exposed healthy seronegative donors. J Immunol (1999) 162:6681-9.
230. Mizukoshi E, Eisenbach C, Edlin BR, Newton KP, Raghuraman S, Weiler-Normann C, et al. Hepatitis C virus (HCV)-specific immune responses of long-term injection drug users frequently exposed to HCV. J Infect Dis (2008) 198:203-12. doi:10.1086/589510
231. Heller T, Werner JM, Rahman F, Mizukoshi E, Sobao Y, Gordon AM, et al. Occupational exposure to hepatitis C virus: early T-cell responses in the absence of seroconversion in a longitudinal cohort study. J Infect Dis (2013) 208:1020-5. doi:10.1093/infdis/jit270
232. Bassett SE, Guerra B, Brasky K, Miskovsky E, Houghton M, Klimpel GR, et al. Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology (2001) 33:1479-87. doi:10.1053/jhep.2001.24371
233. Major ME, Mihalik K, Puig M, Rehermann B, Nascimbeni M, Rice CM, et al. Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. J Virol (2002) 76:6586-95. doi:10.1128/JVI.76.13.6586-6595.2002
234. Nascimbeni M, Mizukoshi E, Bosmann M, Major ME, Mihalik K, Rice CM, et al. Kinetics of CD4+ and CD8+ memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees. J Virol (2003) 77:4781-93. doi:10.1128/JVI.77.8.4781-4793.2003
235. Lanford RE, Guerra B, Chavez D, Bigger C, Brasky KM, Wang XH, et al. Cross-genotype immunity to hepatitis C virus. J Virol (2004) 78:1575-81. doi:10.1128/JVI.78.3.1575-1581.2004
236. Bukh J, Thimme R, Meunier JC, Faulk K, Spangenberg HC, Chang KM, et al. Previously infected chimpanzees are not consistently protected against reinfection or persistent infection after reexposure to the identical hepatitis C virus strain. J Virol (2008) 82:8183-95. doi:10.1128/JVI.00142-08
237. Park SH, Shin EC, Capone S, Caggiari L, De Re V, Nicosia A, et al. Successful vaccination induces multifunctional memory T-cell precursors associated with early control of hepatitis C virus. Gastroenterology (2012) 143(1048-1060):e1044. doi:10.1053/j.gastro.2012.06.005
238. Barth H, Rybczynska J, Patient R, Choi Y, Sapp RK, Baumert TF, et al. Both innate and adaptive immunity mediate protective immunity against hepatitis C virus infection in chimpanzees. Hepatology (2011) 54:1135-48. doi:10.1002/hep.24489
239. Jameson SC, Masopust D. Diversity in T cell memory: an embarrassment of riches. Immunity (2009) 31:859-71. doi:10.1016/j.immuni.2009.11.007
240. Rochman Y, Spolski R, Leonard WJ. New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol (2009) 9:480-90. doi:10.1038/nri2580
241. Pham TN, Macparland SA, Mulrooney PM, Cooksley H, Naoumov NV, Michalak TI. Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol (2004) 78:5867-74. doi:10.1128/JVI.78.11.5867-5874.2004
242. Veerapu NS, Raghuraman S, Liang TJ, Heller T, Rehermann B. Sporadic reappearance of minute amounts of hepatitis C virus RNA after successful therapy stimulates cellular immune responses. Gastroenterology (2011) 140:676.e-85.e. doi:10.1053/j.gastro.2010.10.048
243. Mehta SH, Cox A, Hoover DR, Wang XH, Mao Q, Ray S, et al. Protection against persistence of hepatitis C. Lancet (2002) 359:1478-83. doi:10.1016/S0140-6736(02)08435-0
244. Grebely J, Conway B, Raffa JD, Lai C, Krajden M, Tyndall MW. Hepatitis C virus reinfection in injection drug users. Hepatology (2006) 44:1139-45. doi:10.1002/hep.21376
245. Aitken CK, Lewis J, Tracy SL, Spelman T, Bowden DS, Bharadwaj M, et al. High incidence of hepatitis C virus reinfection in a cohort of injecting drug users. Hepatology (2008) 48:1746-52. doi:10.1002/hep.22534
246. Van De Laar TJ, Molenkamp R, Van Den Berg C, Schinkel J, Beld MG, Prins M, et al. Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam. J Hepatol (2009) 51:667-74. doi:10.1016/j.jhep.2009.05.027
247. Grebely J, Thomas DL, Dore GJ. HCV reinfection studies and the door to vaccine development. J Hepatol (2009) 51:628-31. doi:10.1016/j.jhep.2009.07.002
248. Osburn WO, Fisher BE, Dowd KA, Urban G, Liu L, Ray SC, et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology (2010) 138:315-24. doi:10.1053/j.gastro.2009.09.017
249. Abdel-Hakeem MS, Bedard N, Bruneau J, Shoukry NH. Analysis of a protective immune response during multiple episodes of HCV infection. Abstract Book of the 19th International Symposium on Hepatitis C Virus and Related Viruses. Venice (2012). p. 47. Abstract O.25.
250. Sallusto F, Lanzavecchia A, Araki K, Ahmed R. From vaccines to memory and back. Immunity (2010) 33:451-63. doi:10.1016/j.immuni.2010.10.008
251. Grebely J, Prins M, Hellard M, Cox AL, Osburn WO, Lauer G, et al. Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis (2012) 12:408-14. doi:10.1016/s1473-3099(12)70010-5
252. Grebely J, Morris MD, Rice TM, Bruneau J, Cox AL, Kim AY, et al. Cohort profile: the International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC3) Study. Int J Epidemiol (2013) 42:1649-59. doi:10.1093/ije/dys167
253. Meunier JC, Gottwein JM, Houghton M, Russell RS, Emerson SU, Bukh J, et al. Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus. J Infect Dis (2011) 204:1186-90. doi:10.1093/infdis/jir511
254. Stamataki Z, Coates S, Abrignani S, Houghton M, Mckeating JA. Immunization of human volunteers with hepatitis C virus envelope glycoproteins elicits antibodies that cross-neutralize heterologous virus strains. J Infect Dis (2011) 204:811-3. doi:10.1093/infdis/jir399
255. Law JL, Chen C, Wong J, Hockman D, Santer DM, Frey SE, et al. A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans. PLoS One (2013) 8:e59776. doi:10.1371/journal.pone.0059776
256. Elmowalid GA, Qiao M, Jeong SH, Borg BB, Baumert TF, Sapp RK, et al. Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc Natl Acad Sci U S A (2007) 104:8427-32. doi:10.1073/pnas.0702162104
257. Hansen SG, Piatak M Jr, Ventura AB, Hughes CM, Gilbride RM, Ford JC, et al. Immune clearance of highly pathogenic SIV infection. Nature (2013) 502:100-4. doi:10.1038/nature12519
258. Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka A, et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med (2012) 4:115ra111. doi:10.1126/scitranslmed.3003155
259. Folgori A, Capone S, Ruggeri L, Meola A, Sporeno E, Ercole BB, et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med (2006) 12:190-7. doi:10.1038/nm1353
260. Chmielewska AM, Naddeo M, Capone S, Ammendola V, Hu K, Meredith L, et al. Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regime elicits T cell and neutralizing antibody immune responses. J Virol (2014) 88:5502-10. doi:10.1128/jvi.03574-13